Regeneron Rare Disease Drug and Ultragenyx Gene Therapy Among Recent Regulatory Approvals
Source Summary
Regeneron received U.S. regulatory approval for a drug treating an ultra-rare disease characterized by abnormal bone growth, concluding a three-decade development effort. The article also covers an Ultragenyx gene therapy among other recent pharmaceutical developments.
